Expression profile analysis of prognostic long non-coding RNA in adult acute myeloid leukemia by weighted gene co-expression network analysis (WGCNA)

Conclusions: Prognostic lncRNA-LOC646762, which may contribute to AML through the "endocytosis" signaling pathway, may act as a biomarker for predicting the survival of adult AML patients, as well as for risk stratification.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research

Related Links:

ConclusionThese results highlight an anti-cancer activity of prazosin on AML by inhibiting the PI3K/Akt/mTOR pathway and targeting TNS1.
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
(Karolinska Institutet) A common and inexpensive drug may be used to counteract treatment resistance in patients with acute myeloid leukemia (AML), one of the most common forms of blood cancer. This is the conclusion of a study in mice and human blood cells performed at Karolinska Institutet and SciLifeLab and published in the medical journal EMBO Molecular Medicine. The researchers will now launch a clinical study to test the new combination treatment in patients.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
Abstract Long noncoding RNA (lncRNA) urothelial carcinoma-associated 1 (UCA1) has been identified as an oncogene and is involved in acute myeloid leukemia (AML). Autophagy contributes to tumorigenesis and cancer cell survival. The purpose of this study was to investigate the regulatory role and mechanism of UCA1 in AML cell viability by its effect on autophagy. The expression of UCA1, miR-96-5p, and ATG7 was determined by qRT-PCR and western blot. Cell proliferation was examined by MTT assay. The autophagy level was assessed by green fluorescent protein (GFP)-LC3 immunofluorescence and western blot. The interactio...
Source: Clinical and Experimental Pharmacology and Physiology - Category: Drugs & Pharmacology Authors: Tags: Clin Exp Pharmacol Physiol Source Type: research
We report that the acute myeloid leukemia (AML)-associated CBFβ-SMMHC fusion oncoprotein physically interacts with the PRC1 complex and that these factors co-localize across the AML genome in an apparently PRC2-independent manner. Depletion of CBFβ-SMMHC caused substantial increases in genome-wide PRC1 binding and marked changes in the association between PRC1 and the CBF DNA-binding subunit RUNX1. PRC1 was more likely to be associated with actively transcribed genes in CBFβ-SMMHC-expressing cells. CBFβ-SMMHC depletion had heterogeneous effects on gene expression, including significant reductions in tra...
Source: Cell Reports - Category: Cytology Source Type: research
Conclusions: We show that there are gene region and chromosome specific areas that are preferentially affected or spared by changes in DNA methylation across IDH mutant cancers. This suggests that while IDH mutation causes the same biochemical change in all cancers, the effect may vary in tissue specific fashion. Hypomethylation of enhancers associated with cell differentiation may mediate lack of differentiation in IDH1/2mutant cancers.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Methylation profiling by genome tiling array Homo sapiens Source Type: research
Publication date: 13 January 2020Source: Cancer Cell, Volume 37, Issue 1Author(s): Chi-Chao Chen, Bo Li, Scott E. Millman, Cynthia Chen, Xiang Li, John P. Morris, Allison Mayle, Yu-Jui Ho, Evangelia Loizou, Hui Liu, Weige Qin, Hardik Shah, Sara Violante, Justin R. Cross, Scott W. Lowe, Lingbo ZhangSummaryCancer cells rely on altered metabolism to support abnormal proliferation. We performed a CRISPR/Cas9 functional genomic screen targeting metabolic enzymes and identified PDXK—an enzyme that produces pyridoxal phosphate (PLP) from vitamin B6—as an acute myeloid leukemia (AML)-selective dependency. PDXK kinase a...
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
(Wyss Institute for Biologically Inspired Engineering at Harvard) Acute myeloid leukemia (AML) is a deadly blood cancer that kills most of its victims within five years. Chemotherapy has been the standard treatment for over 40 years, and while it often causes the cancer to go into remission, nearly half of patients experience disease relapse. Scientists at the Wyss Institute and Harvard SEAS have developed an injectable, biomaterial-based vaccine that, when combined with standard chemotherapy, caused complete and lasting recovery from and immunity against AML in mice.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Scientists have discovered that Acute Myeloid Leukemia (AML) grows by taking advantage of the B6 vitamin to accelerate cell division. The research team from Cold Spring Harbor Laboratory (CSHL) and Memorial Sloan Kettering Cancer Center (MSK) suggest they could halt the growth of this cancer by limiting its ability to manipulate the enzyme that pushes B6 to make proteins essential for cell division.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Conclusions: Our data demonstrated that decitabine was effective and relatively safe in treating MDS and AML. Patients with agranulocytosis and severe anemia were prone to have poor survival, which should be monitored in clinical practice.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
Abstract FLT3-ITD+ acute myeloid leukemia (AML) is an important subtype of AML, accounting for approximately 25 % of all AML cases in the world. Recently, increasing evidence has shown that circular RNAs (circRNAs) can act as effective biomarkers of various human cancers. However, the roles of circRNAs in AML remain largely unclear. In the present study, circ_0000370 was found to be significantly increased in FLT3-ITD+ AML and was demonstrated to act as an oncogenic circRNA of AML in vitro. TargetScan results showed that miR-1299, miR-370-3p, miR-502-5p, miR-1281 and miR-640 were potential targets of circ_0000370,...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - Category: Drugs & Pharmacology Authors: Tags: Biomed Pharmacother Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer | Cancer & Oncology | Databases & Libraries | Genetics | Leukemia